CD263 (TRAIL-R3) Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA129165-Each-of-1 | In Stock | ₹ 48,905.50 |
PIPA129165 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 48,905.50
GST (18%): ₹ 8,802.99
Total Price: ₹ 57,708.49
Antigen
CD263 (TRAIL-R3)
Classification
Polyclonal
Conjugate
Unconjugated
Gene
TNFRSF10C
Gene Alias
Antagonist decoy receptor for TRAIL/Apo-2L; CD263; cytotoxic TRAIL receptor-3; DCR1; DCR1-TNFR; Decoy receptor 1; decoy TRAIL receptor without death domain; LIT; lymphocyte inhibitor of TRAIL; MGC149501; MGC149502; TNF receptor superfamily member 10c; TNF-related apoptosis-inducing ligand receptor 3; TNFRSF10C; TRAIL receptor 3; TRAIL receptor without an intracellular domain; TRAILR3; TRAIL-R3; TRID; Tumor necrosis factor receptor superfamily member 10C; tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain; UNQ321/PRO366
Host Species
Rabbit
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
8794
Content And Storage
4° C, do not freeze
Form
Liquid
Applications
Immunohistochemistry (Paraffin)
Concentration
1 mg/mL
Formulation
10mM PBS with 0.2% BSA and 0.1% sodium azide
Gene Accession No.
O14798
Gene Symbols
TNFRSF10C
Immunogen
Synthetic peptide corresponding to the N-terminal extracellular domain of human DcR1 precursor protein
Quantity
500 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Positive Control: Placenta TRAIL-R3 (CD263) is a member of the TNF-receptor superfamily
- This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain
- This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis
- This gene was found to be a p53-regulated DNA damage-inducible gene
- The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.